Spontaneous Bacterial Peritonitis Clinical Trials

Find Spontaneous Bacterial Peritonitis Clinical Trials Near You

To Develop and Validate an Equation for Determination of Major Adverse Kidney Events in Patients With Decompensated Cirrhosis and Ascites- A Prospective Cohort Study

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Acute kidney injury (AKI) is the sudden loss of kidney function that occurs frequently in hospitalised patients with cirrhosis. * It develops in up to 53% and is independently associated with high short-term mortality. * A diagnosis of AKI (even stage 1 AKI) has been shown to be associated with an increased risk of long-term mortality at 30-day, 90-day and 1-year, compared to patients without AKI, even when there is recovery of AKI. * Risk factors with the strongest association for developing AKI include CKD, sepsis, spontaneous bacterial peritonitis (SBP), and presence of ascites. * AKI in cirrhosis is also associated with development of de-novo chronic kidney disease (CKD) , progressive loss of kidney function in patients with pre-existing CKD,recurrent AKI (i.e., AKI on top of CKD) and other organ failures * Kidney dysfunction in patients with cirrhosis is associated with a marked increase in mortality compared with patients without kidney dysfunction. * The accurate estimation of kidney function in patients with cirrhosis is hence crucial for prognosis, treatment strategies, and decisions regarding simultaneous liver-kidney transplantation (SLKT). * Although measured GFR(mGFR) may be ideal for assessing kidney function, it is costly, time-consuming, and challenging to perform frequently in fluctuating kidney function. Therefore, GFR is most commonly estimated using serum creatinine (sCr)-based or cystatin C (CysC)-based equations

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:

• Patients of cirrhosis with ascites with stable renal functions in last 7 days (variability in gfr \< 15 % and no AKI).

Locations
Other Locations
India
Institute of Liver & Biliary Sciences (ILBS)
RECRUITING
New Delhi
Contact Information
Primary
Dr Gnana Kavitha, MD
kavuluj4444@gmail.com
01146300000
Backup
Dr Rakhi Maiwall, DM
rakhi_2011@yahoo.co.in
01146300000
Time Frame
Start Date: 2026-08-31
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 400
Treatments
Cirrhosis with ascites
Patients with cirrhosis and ascites admitted in ILBS.
Sponsors
Leads: Institute of Liver and Biliary Sciences, India

This content was sourced from clinicaltrials.gov

Similar Clinical Trials